Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project

University of Alabama at Birmingham · NCT05989581

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 14–89 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
74
US sites recruiting
1
Study start
April 24, 2024
Record last updated
August 11, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP\<130/80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of \<130/80mmHg or usual care to treatment only if BPs ≥140/90mmHg. For this pilot, the investigator will randomize a total of 74 eligible participants, 37 to active treatment to BP\<130/80mmHg and 37 to usual care.

Being studied: Labetalol or Nifedipine

Conditions: Hypertension in Pregnancy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Viable singleton gestation
  • No fetal anomalies
  • Blood pressures 130-139/80-89mmHg on two occasions at least 4 hours apart prior to 20 weeks gestation
  • Planning to deliver at UAB Hospital
  • No indication for pregnancy termination
  • Receiving care at the UAB prenatal clinics

Exclusion Criteria

  • Declines Randomization
  • Known diagnosis of chronic hypertension ( BP ≥ 140/90mmHg) or current antihypertensive medication use
  • Fetal demise diagnosed prior to enrollment
  • Known major structural of chromosomal abnormalities prior to enrollment
  • Contraindication to first line antihypertensive (Nifedipine/ Labetalol)
  • Comorbidities requiring BP goals \< 130/80mmHg

Recruiting US locations

  • UAB

    Birmingham, AL 35294

    Site contact: Donna Campbell · (205) 996-6268 · dcampbell@uabmc.edu

Study contacts (from the official record)

  • Donna Dunn, PhD · 12058739503 · dcampbell@uabmc.edu
  • Jhana Plump · jplump@uabmc.edu
All heart & blood pressure studies in Alabama →
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project (NCT05989581) | Bored Studies